Artificial intelligence in the radiomic analysis of glioblastomas: A review, taxonomy, and perspective
Frontiers in Oncology, ISSN: 2234-943X, Vol: 12, Page: 924245
2022
- 23Citations
- 273Usage
- 69Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations23
- Citation Indexes23
- 23
- Usage273
- Downloads245
- Abstract Views28
- Captures69
- Readers69
- 69
Review Description
Radiological imaging techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET), are the standard-of-care non-invasive diagnostic approaches widely applied in neuro-oncology. Unfortunately, accurate interpretation of radiological imaging data is constantly challenged by the indistinguishable radiological image features shared by different pathological changes associated with tumor progression and/or various therapeutic interventions. In recent years, machine learning (ML)-based artificial intelligence (AI) technology has been widely applied in medical image processing and bioinformatics due to its advantages in implicit image feature extraction and integrative data analysis. Despite its recent rapid development, ML technology still faces many hurdles for its broader applications in neuro-oncological radiomic analysis, such as lack of large accessible standardized real patient radiomic brain tumor data of all kinds and reliable predictions on tumor response upon various treatments. Therefore, understanding ML-based AI technologies is critically important to help us address the skyrocketing demands of neuro-oncology clinical deployments. Here, we provide an overview on the latest advancements in ML techniques for brain tumor radiomic analysis, emphasizing proprietary and public dataset preparation and state-of-the-art ML models for brain tumor diagnosis, classifications (e.g., primary and secondary tumors), discriminations between treatment effects (pseudoprogression, radiation necrosis) and true progression, survival prediction, inflammation, and identification of brain tumor biomarkers. We also compare the key features of ML models in the realm of neuroradiology with ML models employed in other medical imaging fields and discuss open research challenges and directions for future work in this nascent precision medicine area.
Bibliographic Details
https://digitalscholarship.unlv.edu/ece_fac_articles/1088; https://digitalscholarship.unlv.edu/ece_fac_articles/1104
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85136941909&origin=inward; http://dx.doi.org/10.3389/fonc.2022.924245; http://www.ncbi.nlm.nih.gov/pubmed/35982952; https://www.frontiersin.org/articles/10.3389/fonc.2022.924245/full; https://digitalscholarship.unlv.edu/ece_fac_articles/1088; https://digitalscholarship.unlv.edu/cgi/viewcontent.cgi?article=2091&context=ece_fac_articles; https://digitalscholarship.unlv.edu/ece_fac_articles/1104; https://digitalscholarship.unlv.edu/cgi/viewcontent.cgi?article=2107&context=ece_fac_articles; https://dx.doi.org/10.3389/fonc.2022.924245; https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.924245/full
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know